Aspire Biopharma (ASBP) rebounded over 20% pre-market after a 78% crash. The surge followed a $21 million private placement that restored Nasdaq compliance. Additionally, the firm secured a $22.5 million credit facility to acquire Dura Control Systems without further equity raises, boosting investor confidence significantly.